Urovant Sciences to Report 2018 Third Fiscal Quarter Financial Results

BASEL, Switzerland & IRVINE, Calif.–(BUSINESS WIRE)–Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for urologic conditions, today announced it will
report 2018 third fiscal quarter financial results after the close of
U.S. financial markets on Wednesday, February 13, 2019.

Management will host a conference call and live webcast to discuss
Urovant’s financial results at 1:30 p.m. Pacific Time that same day. A
question and answer session will follow management’s remarks.

The conference call numbers are (866) 470-1049 for domestic callers and
(409) 217-8245 for international callers. The conference ID is 3197868.

A replay of the call will be available approximately four hours after
the call and accessible for 7 days at (855) 859-2056, conference ID
3197868. A webcast will be archived on the Investor Relations page of
the Urovant Sciences website immediately after the call and available
for at least 30 days.

Urovant Sciences R&D Day Webcast February 7, 2019

For institutional investors and financial analysts interested in
learning more about Urovant, the company invites you to participate in
its R&D Day webcast February 7, 2019, 9:00 – 11:30 a.m. Pacific Time /
noon – 2:30 p.m. Eastern Time. Register for the webcast here.

This webcast will be archived on the Investor Relations page of the
Urovant Sciences website.

About Urovant Sciences

Urovant Sciences is a clinical-stage biopharmaceutical company focused
on developing and commercializing innovative therapies for urologic
conditions. Urovant’s lead product candidate, vibegron, is an oral,
once-daily, small molecule beta-3 agonist being evaluated for the
treatment of overactive bladder (OAB) with symptoms of urge urinary
incontinence, urgency, and urinary frequency; for OAB in men with benign
prostatic hyperplasia; and for abdominal pain associated with irritable
bowel syndrome. Urovant has licensed global rights, excluding Japan and
certain Asian territories, for the development and commercialization of
vibegron. Urovant’s second product candidate, URO-902, is a novel gene
therapy being developed for patients with OAB who have failed oral
pharmacological therapy. Urovant intends to develop treatments for
additional urologic diseases. For more information, please visit www.urovant.com.

Contacts

Investor inquiries: [email protected]

error: Content is protected !!